Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7768)
All Articles published online
|
Publishing Process of This Article
|
Feb 21, 2015 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v21/i7/2096.htm |
| Number | Citing Articles |
| 1 |
Richard Kim, E Gabriela Chiorean, Manik Amin, Caio Max S Rocha-Lima, Jitendra Gandhi, William P Harris, Tao Song, David Portnoy. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. British Journal of Cancer 2017; 117(2): 189 doi: 10.1038/bjc.2017.160
|
| 2 |
Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World Journal of Gastrointestinal Oncology 2020; 12(1): 83-91 doi: 10.4251/wjgo.v12.i1.83
|
| 3 |
Ioannis Ntanasis-Stathopoulos, Diamantis I Tsilimigras, Maria Gavriatopoulou, Dimitrios Schizas, Timothy M Pawlik. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy 2020; 20(9): 765 doi: 10.1080/14737140.2020.1807333
|
| 4 |
L.-J. Palmieri, J. Lavolé, S. Dermine, C. Brezault, M. Dhooge, A. Barré, S. Chaussade, R. Coriat. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy. Pharmacology & Therapeutics 2020; 210: 107517 doi: 10.1016/j.pharmthera.2020.107517
|
| 5 |
Florian Moik, Jakob M. Riedl, Thomas Winder, Angelika Terbuch, Christopher H. Rossmann, Joanna Szkandera, Thomas Bauernhofer, Anne-Katrin Kasparek, Renate Schaberl-Moser, Andreas Reicher, Felix Prinz, Martin Pichler, Herbert Stöger, Michael Stotz, Armin Gerger, Florian Posch. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-42069-1
|
| 6 |
Pamela Minicozzi, Tiziana Cassetti, Claudia Vener, Milena Sant. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiology 2018; 55: 52 doi: 10.1016/j.canep.2018.04.011
|
| 7 |
Jie Ying, Jinfei Chen. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data. Critical Reviews in Oncology/Hematology 2019; 139: 134 doi: 10.1016/j.critrevonc.2019.01.001
|
| 8 |
G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann. Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms. Der Chirurg 2018; 89(11): 858 doi: 10.1007/s00104-018-0718-y
|
| 9 |
Nicolas Roussot, Julie Vincent, Remi Palmier, Guillaume Constantin, Leila Bengrine, Jean-David Fumet, François Ghiringhelli. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1293670
|
| 10 |
Li-Ye Wang, Shuai Gong, Li-Ping Gao, Li-Xia Hou, Wei He. Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy. Medicine 2018; 97(49): e13372 doi: 10.1097/MD.0000000000013372
|
| 11 |
M. Tampellini, A. La Salvia, G. V. Scagliotti. Novel investigational therapies for treating biliary tract carcinoma. Expert Opinion on Investigational Drugs 2016; 25(12): 1423 doi: 10.1080/13543784.2016.1252330
|
| 12 |
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer. Targeted Oncology 2023; 18(6): 837 doi: 10.1007/s11523-023-01000-5
|
| 13 |
Nicholas Holt, Joanna Lee, Ngee Soon Lau, Natalie Collier, Oliver M. Fisher, Carlo Pulitano, Katrin Sjoquist, Craig Philip I.. Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e. 2024; : 407 doi: 10.1002/9781119756422.ch21
|
| 14 |
Maria Maddalena Simile, Paola Bagella, Gianpaolo Vidili, Angela Spanu, Roberto Manetti, Maria Antonietta Seddaiu, Sergio Babudieri, Giordano Madeddu, Pier Andrea Serra, Matteo Altana, Panagiotis Paliogiannis. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina 2019; 55(2): 42 doi: 10.3390/medicina55020042
|
| 15 |
Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Alexander Lim, Richard Kim. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opinion on Investigational Drugs 2018; 27(9): 709 doi: 10.1080/13543784.2018.1512581
|
| 16 |
Valeria Simone, Oronzo Brunetti, Luigi Lupo, Mario Testini, Eugenio Maiorano, Michele Simone, Vito Longo, Christian Rolfo, Marc Peeters, Aldo Scarpa, Amalia Azzariti, Antonio Russo, Domenico Ribatti, Nicola Silvestris. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. International Journal of Molecular Sciences 2017; 18(2): 418 doi: 10.3390/ijms18020418
|
| 17 |
Pedro Luiz Serrano Uson Junior, Tanios Bekaii-Saab. Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?. Immunotherapy 2023; 15(7): 531 doi: 10.2217/imt-2022-0201
|
| 18 |
Giovanni Brandi, Michela Venturi, Maria Abbondanza Pantaleo, Giorgio Ercolani, Lorenzo Fornaro, Nicola Silvestris, Francesco Leone, Enrico Vasile, Sara Lonardi, Stefano Cereda, Daniele Santini, Giuseppe Aprile. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. Digestive and Liver Disease 2016; 48(3): 231 doi: 10.1016/j.dld.2015.11.017
|
| 19 |
Brinda Balasubramanian, Simran Venkatraman, Kyaw Zwar Myint, Tavan Janvilisri, Kanokpan Wongprasert, Supeecha Kumkate, David O. Bates, Rutaiwan Tohtong. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals 2021; 14(1): 51 doi: 10.3390/ph14010051
|
| 20 |
Philipp Heumann, Andreas Albert, Karsten Gülow, Denis Tümen, Martina Müller, Arne Kandulski. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma. Cancers 2024; 16(9): 1690 doi: 10.3390/cancers16091690
|
| 21 |
José María Huguet, Miriam Lobo, José Mir Labrador, Carlos Boix, Cecilia Albert, Luis Ferrer-Barceló, Ana B Durá, Patricia Suárez, Isabel Iranzo, Mireia Gil-Raga, Celia Baez de Burgos, Javier Sempere. Diagnostic-therapeutic management of bile duct cancer. World Journal of Clinical Cases 2019; 7(14): 1732-1752 doi: 10.12998/wjcc.v7.i14.1732
|
| 22 |
Leonard M. Quinn, Nicholas Bird, Robert Jones, David Vass, Hassan Malik. Liver Cancers. 2019; : 199 doi: 10.1007/978-3-319-92216-4_16
|
| 23 |
Anwaar Saeed, Robin Park, Mohammed Al-Jumayli, Raed Al-Rajabi, Weijing Sun. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clinical Colorectal Cancer 2019; 18(2): 81 doi: 10.1016/j.clcc.2019.02.005
|
| 24 |
Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World Journal of Gastrointestinal Oncology 2020; 12(1): 83-91 doi: 10.4251/wjgo.v12.i1.83
|
| 25 |
Grégoire Marret, Cindy Neuzillet, Benoît Rousseau, Christophe Tournigand. Traitements médicaux des cholangiocarcinomes en 2015. Bulletin du Cancer 2016; 103(4): 389 doi: 10.1016/j.bulcan.2016.01.019
|
| 26 |
Margherita Rimini, Andrea Casadei-Gardini. Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opinion on Investigational Drugs 2021; 30(4): 411 doi: 10.1080/13543784.2021.1881479
|
| 27 |
Luca Maroni, Marco Marzioni. Diagnosis and Management of Cholangiocarcinoma. 2021; : 555 doi: 10.1007/978-3-030-70936-5_26
|
| 28 |
Yong-Na Wu, Li-Hong He, Zhong-Tian Bai, Xun Li. <p>NRP1 is a Prognostic Factor and Promotes the Growth and Migration of Cells in Intrahepatic Cholangiocarcinoma</p>. Cancer Management and Research 2020; : 7021 doi: 10.2147/CMAR.S260091
|
| 29 |
Pashtoon Murtaza Kasi. Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies. Case Reports in Oncology 2020; 13(2): 941 doi: 10.1159/000509075
|
| 30 |
Cindy Neuzillet, Benoît Rousseau, Hemant Kocher, Philippe Bourget, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacology & Therapeutics 2017; 174: 145 doi: 10.1016/j.pharmthera.2017.02.028
|
| 31 |
Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li. Systemic treatment of advanced or recurrent biliary tract cancer. BioScience Trends 2020; 14(5): 328 doi: 10.5582/bst.2020.03240
|
| 32 |
Concetta Elisa Onesti, Adriana Romiti, Michela Roberto, Rosa Falcone, Paolo Marchetti. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy 2015; 15(10): 1183 doi: 10.1586/14737140.2015.1081816
|
| 33 |
Margherita Rimini, Marco Puzzoni, Federica Pedica, Nicola Silvestris, Lorenzo Fornaro, Giuseppe Aprile, Eleonora Loi, Oronzo Brunetti, Caterina Vivaldi, Francesca Simionato, Patrizia Zavattari, Mario Scartozzi, Valentina Burgio, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Andrea Casadei-Gardini. Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology & Hepatology 2021; 15(12): 1367 doi: 10.1080/17474124.2021.1991313
|
| 34 |
Angélique Vienot, Cindy Neuzillet. Continuum of care for advanced biliary tract cancers. Clinics and Research in Hepatology and Gastroenterology 2020; 44(6): 810 doi: 10.1016/j.clinre.2020.05.009
|
| 35 |
Gabriel Allo, Ahu Can, Roger Wahba, Nils Vogel, Tobias Goeser, Fabian Kütting, Dirk Waldschmidt. Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil in advanced biliary tract cancers. Molecular and Clinical Oncology 2021; 16(2) doi: 10.3892/mco.2021.2485
|
| 36 |
L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6142-y
|
| 37 |
Marc Hilmi, Angélique Vienot, Benoît Rousseau, Cindy Neuzillet. Immune Therapy for Liver Cancers. Cancers 2019; 12(1): 77 doi: 10.3390/cancers12010077
|
| 38 |
Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal. Second-line therapies in advanced biliary tract cancers. The Lancet Oncology 2020; 21(1): e29 doi: 10.1016/S1470-2045(19)30733-8
|
| 39 |
Roberto Filippi, Pasquale Lombardi, Virginia Quarà, Elisabetta Fenocchio, Giacomo Aimar, Michela Milanesio, Francesco Leone, Massimo Aglietta. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opinion on Pharmacotherapy 2019; 20(17): 2121 doi: 10.1080/14656566.2019.1667335
|
| 40 |
Linde Kehmann, Marie-Luise Berres, Maria Gonzalez-Carmona, Dominik P. Modest, Raphael Mohr, Alexander Wree, Marino Venerito, Christian Strassburg, Verena Keitel, Christian Trautwein, Tom Luedde, Christoph Roderburg. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10972-6
|
| 41 |
Jennifer Yang, Matthew R. Farren, Daniel Ahn, Tanios Bekaii-Saab, Gregory B. Lesinski. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opinion on Therapeutic Targets 2017; 21(5): 485 doi: 10.1080/14728222.2017.1306055
|
| 42 |
Lorenzo Fornaro, Caterina Vivaldi, Stefano Cereda, Francesco Leone, Giuseppe Aprile, Sara Lonardi, Nicola Silvestris, Daniele Santini, Michele Milella, Chiara Caparello, Gianna Musettini, Giulia Pasquini, Alfredo Falcone, Giovanni Brandi, Isabella Sperduti, Enrico Vasile. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental & Clinical Cancer Research 2015; 34(1) doi: 10.1186/s13046-015-0267-x
|
| 43 |
John R. Bergquist, Tommy Ivanics, Curtis B. Storlie, Ryan T. Groeschl, May C. Tee, Elizabeth B. Habermann, Rory L. Smoot, Michael L. Kendrick, Michael B. Farnell, Lewis R. Roberts, Gregory J. Gores, David M. Nagorney, Mark J. Truty. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. Journal of Surgical Oncology 2016; 114(4): 475 doi: 10.1002/jso.24381
|
| 44 |
Ester Oneda, Mohammed Abu Hilal, Alberto Zaniboni. Biliary Tract Cancer: Current Medical Treatment Strategies. Cancers 2020; 12(5): 1237 doi: 10.3390/cancers12051237
|
| 45 |
Abdullah Esmail, Mohamed Badheeb, Batool Wael Alnahar, Bushray Almiqlash, Yara Sakr, Ebtesam Al-Najjar, Ali Awas, Mohammad Alsayed, Bayan Khasawneh, Mohammed Alkhulaifawi, Amneh Alsaleh, Ala Abudayyeh, Yaser Rayyan, Maen Abdelrahim. The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma. Pharmaceuticals 2024; 17(7): 910 doi: 10.3390/ph17070910
|
| 46 |
Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito, Matteo Landriscina. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives. Molecules 2020; 25(16): 3754 doi: 10.3390/molecules25163754
|
| 47 |
Urvi A. Shah, Amara G. Nandikolla, Lakshmi Rajdev. Immunotherapeutic Approaches to Biliary Cancer. Current Treatment Options in Oncology 2017; 18(7) doi: 10.1007/s11864-017-0486-9
|
| 48 |
Audrey E Kam, Ashiq Masood, Rachna T Shroff. Current and emerging therapies for advanced biliary tract cancers. The Lancet Gastroenterology & Hepatology 2021; 6(11): 956 doi: 10.1016/S2468-1253(21)00171-0
|
| 49 |
Aram A. Musaelyan, Ekaterina M. Anokhina, Alina I. Turdubaeva, Natalia V. Mitiushkina, Anastasia N. Ershova, Anna D. Shestakova, Aigul R. Venina, Evgeny N. Imyanitov, Sergey V. Orlov. Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report. Exploration of Targeted Anti-tumor Therapy 2024; 5(3): 780 doi: 10.37349/etat.2024.00246
|
| 50 |
Changqing Xie, Nicole A. McGrath, Cecilia Monge Bonilla, Jianyang Fu. Systemic treatment options for advanced biliary tract carcinoma. Journal of Gastroenterology 2020; 55(10): 944 doi: 10.1007/s00535-020-01712-9
|
| 51 |
Adriana Romanzi, Erica Villa. Angiogenesis: the Yin and Yang in intrahepatic cholangiocarcinoma. Hepatoma Research 2023; doi: 10.20517/2394-5079.2023.53
|
| 52 |
Aslam Ejaz, Jordan M. Cloyd, Timothy M. Pawlik. Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology 2020; 27(2): 552 doi: 10.1245/s10434-019-07873-z
|
| 53 |
Loic Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka, Charles Ferté. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. European Journal of Cancer 2017; 81: 161 doi: 10.1016/j.ejca.2017.05.006
|
| 54 |
Jang Han Jung, Hee Seung Lee, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer. Chemotherapy 2017; 62(6): 361 doi: 10.1159/000479425
|